FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

(II	IIE2	AND	EXCHANGE	COMMISSION

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response:

5. Relationship of Reporting Person(s) to Issuer

0.5

Check this box if no longer subjetility Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	
--	--

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) See Instruction 10.

1. Name and Address of Reporting Person

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

Bassler Bonnie L					REGENERON PHARMACEUTICALS, INC. [REGN]							- I`.	✓ Direc	Director Officer (give title below)		10% Ov Other (s		
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 08/15/2024										below	below)	
(Street) TARRYTOWN NY 10591 (City) (State) (Zip)					4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable le) Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deriv	ative S	ecurities A	cqu	ired,	Dis	posed	of,	or Ben	eficia	ly Owne	d			
Date				action Day/Year)	2A. Deemed Execution Date if any (Month/Day/Yea	,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				Securit Benefic Owned	Securities For Beneficially (D)		n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount		(A) or (D)	Price			Transa		
Common Stock 08				08/15	/2024			M ⁽¹⁾		756		A	\$371	.4 2	2,138		D	
Common Stock 08/				08/15	/2024			S ⁽¹⁾		756 D		\$1,17	0 1	1,382		D		
		T				curities Acc								Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deem Executior if any (Month/Da	Date,	4. Transacti Code (Ins 8)		Exp	Date Ex piration onth/Da	Date		Am Sec Un De	Title and mount of ocurities nderlying privative S estr. 3 and		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

\$371.4

Oualified Stock

Option

(right to buy)

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024.
- 2. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.

Exercisable

(2)

(A) (D)

756

/s/**Bonnie L. Bassler

08/16/2024

1,516

D

** Signature of Reporting Person

or Number of Shares

756

\$0.0

Title

01/02/2029

Common

Stock

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

08/15/2024

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

 $M^{(1)}$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.